Understanding intrinsic and acquired resistance to anti-FGFR therapies

体外和体内临床前数据表明，抑制子宫内膜癌患者的FGFR可能是一种可行的治疗方法。来自其他癌症的数据表明，尽管最初对激酶抑制剂有显著的反应，但癌细胞最终会产生耐药性。该项目旨在确定和表征FGFR抑制后出现的耐药机制，以便设计可能延迟和/或防止耐药出现的联合疗法。

In vitro and in vivo preclinical data suggests that inhibition of FGFR in endometrial cancer patients may be a viable therapeutic approach. Data from other cancers suggests that despite remarkable initial responses to kinase inhibitors, cancer cells eventually develop resistance. This project aims to identify and characterize the mechanisms of resistance that emerge following FGFR inhibition in order to design combination therapies that may delay and/or prevent the emergence of resistance.